The week in review: July 10-14
This week, Psychiatric times discussed a wide variety of psychiatric issues and industry updates, from noninvasive brain stimulation techniques for catatonia to the concurrent treatment of eating disorders and PTSD.…
EMA review of suicide risk for Ozempic, Saxenda extended to other GLP-1 receptor agonists | Biospace
Pictured: The EMA building at its old headquarters in London/iStock, Lubo Ivanko The European Medicines Agency has extended its review of a potential suicide risk associated with Novo Nordisk’s Ozempic…